Anti-PEX7 Antibody
- 产品详情
- 实验流程
Application
| WB, IHC, IF/IC |
|---|---|
| Primary Accession | O00628 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 35892 Da |
| Gene ID | 5191 |
|---|---|
| Other Names | PTS2R; Peroxisomal targeting signal 2 receptor; PTS2 receptor; Peroxin-7 |
| Target/Specificity | KLH-conjugated synthetic peptide encompassing a sequence within the center region of human PEX7. The exact sequence is proprietary. |
| Dilution | WB~~WB (1/500 - 1/1000) IHC~~1:100~500 IF/IC~~N/A |
| Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | PEX7 {ECO:0000303|PubMed:9090383, ECO:0000312|HGNC:HGNC:8860} |
|---|---|
| Function | Receptor required for the peroxisomal import of proteins containing an N-terminal PTS2-type peroxisomal targeting signal (PubMed:11931631, PubMed:22057399, PubMed:25538232, PubMed:9090381, PubMed:40739340). Specifically binds to cargo proteins containing a PTS2 peroxisomal targeting signal in the cytosol (PubMed:11931631, PubMed:22057399, PubMed:25538232). Cargo protein-binding triggers interaction with PEX5 and formation of a ternary complex composed of PEX5 and PEX7 along with PTS2-containing cargo proteins, which is translocated into peroxisomes by passing through the PEX13-PEX14 docking complex (PubMed:11546814, PubMed:25538232). |
| Cellular Location | Cytoplasm, cytosol. Peroxisome matrix. Note=Translocated into the peroxisome matrix together with PTS2-containing cargo proteins and PEX5 |
| Tissue Location | Ubiquitous (PubMed:9090381). Highest expression in pancreas, skeletal muscle and heart (PubMed:9090381) |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Purdue P.E.,et al.Nat. Genet. 15:381-384(1997).
Braverman N.,et al.Nat. Genet. 15:369-376(1997).
Braverman N.,et al.Genomics 63:181-192(2000).
van den Brink D.M.,et al.Am. J. Hum. Genet. 72:471-477(2003).
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,250.00
Cat# AP51424
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。